Parallelized sample processing and library prep
US-12097501-B2 · Sep 24, 2024 · US
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
US8940871B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8940871-B2 |
| Application number | US-29386007-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 20, 2007 |
| Priority date | Mar 20, 2006 |
| Publication date | Jan 27, 2015 |
| Grant date | Jan 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody that binds to Prostate Stem Cell Antigen (PSCA) comprising: a light chain CDR1 of a CDR1 in SEQ ID NO: 6; a light chain CDR2 of a CDR2 in SEQ ID NO: 6; a light chain CDR3 of a CDR3 in SEQ ID NO: 6; a heavy chain CDR1 of a CDR1 in SEQ ID NO: 7; a heavy chain CDR2 of a CDR2 in SEQ ID NO: 7; and a heavy chain CDR3 of a CDR3 in SEQ ID NO: 7. 2. The antibody of claim 1 comprising a variable light chain region of SEQ I…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8940871B2 cover?
- The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and …
- Who is the assignee on this patent?
- Wu Anna M, Reiter Robert E, Univ California
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57555. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).